DaVita Inc. (DVA) KPIs and segments
Close on Nov 17, 2026Market cap $10.88BP/E 12.7Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của DaVita · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của DaVita: 57 chỉ số vận hành, trong đó có U.S. Dialysis Treatments, U.S. Average Treatments per Treatment Day và U.S. Average Treatments per Normalized Day, lấy từ 180 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
U S Dialysis And Related Lab Services with Intersegment($M) | 3,050 | 3,012 | 2,942 | 2,980 | 2,913 | 2,823 | 2,906 | 2,841 | 2,756 | ||||
U. S. Dialysis And Related Lab Services($M) | 3,028 | 3,000 | 2,921 | 2,968 | 2,897 | 2,811 | 2,890 | 2,828 | |||||
U S Dialysis($M) | 2,811 | 2,816 | 2,906 | 2,841 | 2,732 | 2,721 | |||||||
Other Operating Segments with Intersegment($M) | 552 | 557 | 498 | 567 | 455 | 486 | 415 | 430 | 376 | 362 | 342 | ||
Other Operating Segment($M) | 550 | 554 | 494 | 564 | 452 | 483 | 412 | 425 | 374 | 359 | 339 | 358 | |
U. S. Dialysis And Related Lab Services($M) | 544 | 538 | 506 | 530 | 523 | 476 | 549 | 550 | |||||
U S Dialysis($M) | 476 | 496 | 549 | 550 | 526 | 444 | |||||||
Other Operating Segment($M) | -18.6 | 57.1 | 5.83 | 37.3 | 1.22 | 56.7 | -2.81 | 98.8 | 13.9 | -18.6 | -11.5 | 9.63 | |
Other Operating Segment($M) | -33.2 | -28.7 | -13.6 | -23.5 | -33.3 | -17.8 | -29.7 | -31.9 | -19.2 | -18.5 | -16.1 | -21.7 | |
U S Dialysis($M) | -114 | -139 | -120 | -106 | -105 | -137 | |||||||
U. S. Dialysis And Related Lab Services($M) | -126 | -141 | -88.4 | -133 | -103 | -114 | -120 | ||||||
U.S. Dialysis Treatments2 | 7,329,644 | 7,226,600 | 7,029,525 | 7,264,520 | 7,242,725 | 7,186,217 | 7,040,519 | 7,278,605 | 7,350,784 | 7,265,444 | 7,151,512 | 7,254,559 | |
U.S. Dialysis Treatment Days(ngày) | 79 | 78 | 77 | 79 | 79 | 78 | 77 | 79 | 79 | 78 | 78 | 78 | |
U.S. Normalized Treatment Days(ngày) | 79 | 78 | 77 | 80 | 79 | 77 | |||||||
U.S. Average Treatments per Treatment Day1 | 92,780 | 92,649 | 91,650 | 91,608 | 91,680 | 92,131 | 91,793 | 91,786 | 93,048 | 93,147 | 92,159 | 92,533 | |
U.S. Treatments per Day YoY Growth(%) | 1.2% | 0.6% | -0.2% | -0.2% | -1.5% | -1.1% | -0.4% | -0.8% | 0.6% | 0.5% | -0.3% | 1.0% | |
U.S. Average Treatments per Normalized Day1 | 92,546 | 92,649 | 91,889 | 91,378 | 91,913 | 91,554 | |||||||
U.S. Treatments per Normalized Day YoY Growth(%) | 0.7% | 0.6% | 0.4% | -0.7% | -1.0% | -0.8% | |||||||
U.S. Normalized Non-Acquired Treatment Growth YoY(%) | 0.4% | 0.3% | 0.1% | -0.6% | -0.6% | -0.8% | -0.6% | -0.3% | -0.2% | 0.4% | 0.4% | 0.7% | |
Total Global Outpatient Dialysis Patients | 298,100 | 298,500 | 296,300 | 295,000 | 293,200 | 283,100 | 282,000 | 281,100 | 265,400 | 265,100 | 258,600 | 250,200 | |
Total Global Outpatient Dialysis Centers2 | 3,269 | 3,266 | 3,262 | 3,242 | 3,247 | 3,175 | 3,173 | 3,166 | 3,113 | 3,124 | 3,092 | 3,042 | |
U.S. Outpatient Dialysis Centers (Ending)6 | 2,671 | 2,671 | 2,666 | 2,657 | 2,662 | 2,662 | 2,661 | 2,657 | 2,660 | 2,672 | 2,665 | 2,675 | |
U.S. Centers Operated at Beginning of Period | 2,671 | 2,666 | 2,657 | 2,662 | 2,662 | 2,661 | 2,657 | 2,660 | 2,672 | 2,665 | 2,675 | 2,694 | |
U.S. Centers Acquired | 2 | 1 | 7 | 0 | 0 | 0 | 1 | 0 | 0 | -6 | 9 | 0 | |
U.S. Centers Developed (De Novo) | 3 | 2 | 2 | 9 | 0 | -3 | 6 | 10 | -4 | 5 | 2 | 15 | |
U.S. Centers Net Change in Non-Owned Managed Centers | -1 | 0 | 0 | 0 | 0 | -2 | 1 | 0 | 0 | 0 | -8 | 2 | |
U.S. Centers Sold and Closed (Consolidated) | 0 | 0 | 0 | 0 | 0 | 0 | -3 | -10 | -1 | 7 | -8 | 0 | |
U.S. Centers Closed (Non-Owned Managed) | -2 | 0 | 0 | -9 | -1 | -1 | -1 | -11 | -11 | 3 | -5 | -51 | |
International Outpatient Dialysis Centers (Ending)7 | 598 | 595 | 596 | 585 | 2,662 | 2,662 | 512 | 509 | 2,660 | 2,672 | 427 | 367 | |
International Countries of Operation | 14 | 14 | 14 | 14 | 14 | 13 | 13 | 13 | 13 | 13 | 12 | 11 | |
International Centers Operated at Beginning of Period | 595 | 596 | 585 | 2,662 | 2,662 | 512 | 509 | 2,660 | 2,672 | 427 | 367 | 2,694 | |
International Centers Acquired | 2 | 4 | 9 | 60 | 0 | 1 | 1 | 186 | 0 | -55 | 67 | 0 | |
International Centers Developed (De Novo) | 1 | 1 | 1 | -5 | 3 | 0 | 0 | -7 | 3 | 0 | 0 | -10 | |
International Centers Net Change in Non-Owned Managed Centers | 4 | 0 | 2 | 0 | 0 | 0 | 4 | -39 | 0 | -5 | -3 | -1 | |
International Centers Sold and Closed (Consolidated) | -3 | -4 | -1 | -10 | 0 | -1 | -2 | 5 | -2 | 0 | 0 | 1 | |
International Centers Closed (Non-Owned Managed) | -1 | 0 | 0 | -2 | -3 | 0 | 0 | 12 | -13 | -3 | -4 | 45 | |
U.S. Dialysis Average Patient Service Revenue per Treatment($) | 415 | 416 | 418 | 423 | 411 | 405 | 400 | 396 | 394 | 390 | 385 | 386 | |
U.S. Dialysis Patient Care Costs per Treatment($) | 280 | 277 | 280 | 280 | 274 | 268 | 272 | 265 | 257 | 255 | 255 | 263 | |
U.S. Dialysis General and Administrative Expenses per Treatment($) | 43.14 | 45.79 | 45.49 | 46.28 | 44.51 | 43.43 | 40.15 | 43.44 | 41.01 | 38.79 | 38.39 | 39.06 | |
U.S. Dialysis Depreciation and Amortization per Treatment($) | 19.70 | 20.26 | 22.07 | 22.50 | 21.57 | 21.82 | 22.28 | 21.62 | 23.21 | 22.08 | 24.17 | 24.94 | |
U.S. Dialysis Total Operating Revenues($M)2 | 3,050 | 3,012 | 2,942 | 3,076 | 2,980 | 2,913 | 2,823 | 2,888 | 2,906 | 2,841 | 2,756 | 2,809 | |
U.S. Dialysis Patient Service Revenues($M)4 | 3,044 | 3,005 | 2,935 | 3,070 | 2,974 | 2,907 | 2,817 | 2,881 | 2,900 | 2,835 | 2,750 | 2,802 | |
Medicare and Medicare Advantage (U.S. Dialysis Patient Service Revenue)($M) | 1,756 | 1,749 | 1,675 | 1,757 | 1,715 | 1,660 | 1,609 | 1,615 | 1,642 | 1,587 | 1,532 | 1,562 | |
Medicaid and Managed Medicaid (U.S. Dialysis Patient Service Revenue)($M) | 228 | 227 | 213 | 233 | 215 | 218 | 207 | 222 | 217 | 215 | 210 | 205 | |
Other Government (U.S. Dialysis Patient Service Revenue)($M) | 89.9 | 88.8 | 92.9 | 103 | 87 | 83.1 | 76.7 | 94.1 | 86.7 | 80.3 | 82.6 | 89.2 | |
Commercial Payors (U.S. Dialysis Patient Service Revenue)($M) | 970 | 940 | 954 | 978 | 957 | 947 | 925 | 951 | 955 | 953 | 926 | 947 | |
U.S. Dialysis Other Revenues($M)1 | 7 | 7 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | |
Management and Administrative Service Fees (U.S. Dialysis)($M) | 6.80 | 6.50 | 6.30 | 6.40 | 6.30 | 6 | 6 | 6.10 | 6.20 | 5.90 | 6.10 | 6.40 | |
U.S. Dialysis Total Operating Expenses($M)4 | 2,506 | 2,474 | 2,436 | 2,521 | 2,450 | 2,391 | 2,347 | 2,392 | 2,357 | 2,291 | 2,230 | 2,365 | |
U.S. Dialysis Patient Care Costs($M) | 2,054 | 2,005 | 1,969 | 2,031 | 1,981 | 1,928 | 1,913 | 1,926 | 1,893 | 1,855 | 1,825 | 1,909 | |
U.S. Dialysis General and Administrative Expenses($M) | 316 | 331 | 320 | 336 | 322 | 312 | 283 | 316 | 301 | 282 | 275 | 283 | |
U.S. Dialysis Depreciation and Amortization($M) | 144 | 146 | 155 | 163 | 156 | 157 | 157 | 157 | 171 | 160 | 173 | 181 | |
U.S. Dialysis Equity Investment Income($M) | -8 | -8 | -8 | -10 | -10 | -7 | -6 | -8 | -8 | -6 | -6 | -8 | |
U.S. Dialysis Segment Operating Income($M) | 544 | 538 | 506 | 556 | 530 | 523 | 476 | 496 | 549 | 550 | 526 | 444 | |
U.S. Dialysis Patient Accounts Receivable($M)1 | 1,684 | 1,719 | 1,695 | 1,610 | 1,704 | 1,838 | 1,722 | 1,615 | 1,707 | 1,812 | 2,180 | 1,632 | |
U.S. Dialysis Days Sales Outstanding (DSO)(ngày) | 51 | 52 | 52 | 49 | 53 | 58 | 55 | 52 | 54 | 59 | 73 | 54 | |
IKC Patients in Risk-Based Integrated Care Arrangements2 | 80,800 | 64,900 | 62,600 | 66,000 | 64,900 | 64,400 | 62,100 | 70,400 | 69,500 | 71,300 | 68,600 | 58,000 | |
IKC Annualized Medical Spend Under Risk-Based Arrangements($M) | 6,400 | 5,800 | 5,400 | 5,600 | 5,500 | 5,300 | 5,200 | 5,501 | 5,400 | 5,400 | 5,300 | 4,600 | |
IKC Patients in Other Integrated Care Arrangements | 3,100 | 5,700 | 6,300 | 9,400 | 9,400 | 9,300 | 9,300 | 11,600 | 13,900 | 15,200 | 14,200 | 17,000 | |
Total Ancillary Services and International Operating Revenues($M)4 | 557 | 1,606 | 1,054 | 415 | 1,922 | 1,355 | 901 | 342 | 1,510 | 1,080 | 704 | 284 | |
U.S. Integrated Kidney Care (IKC) Revenues($M)1 | 144 | 162 | 116 | 190 | 94 | 152 | 105 | 165 | 112 | 114 | 115 | 160 | |
Ancillary Other Revenues — Medicare & MA (IKC Shared Savings)($M) | 137 | 152 | 109 | 183 | 85.9 | 140 | 99 | 159 | 104 | 97.4 | 103 | 143 | |
U.S. Other Ancillary Services Revenues($M)1 | 10 | 9 | 10 | 10 | 9 | 8 | 7 | 7 | 6 | 7 | 7 | 7 | |
Ancillary Other Revenues — Clinical Research & Transplant Software($M) | 23.8 | 26.2 | 27.6 | 33.8 | 29 | 21.1 | 15.6 | 14.7 | 13.5 | 15.5 | 15.2 | 14.6 | |
International Dialysis Operations Revenues($M)2 | 398 | 386 | 372 | 367 | 352 | 325 | 302 | 258 | 258 | 242 | 219 | 194 | |
Ancillary Patient Service Revenues — Other Government (International)($M) | 253 | 236 | 248 | 242 | 238 | 225 | 210 | 199 | 196 | 177 | 146 | 124 | |
Ancillary Patient Service Revenues — Commercial (International)($M) | 134 | 136 | 110 | 108 | 98.6 | 91.2 | 87.8 | 56.8 | 58.6 | 62.4 | 70.2 | 67.7 | |
Intersegment Revenue Eliminations($M) | -24 | -14 | -24 | -23 | -15 | -20 | -14 | -23 | -19 | -17 | -27 | -24 | |
Total Ancillary Services and International Operating Loss($M)3 | 57 | 44 | 63 | -3 | 92 | 55 | 54 | -12 | 83 | -16 | -30 | -25 | |
U.S. Integrated Kidney Care (IKC) Operating (Loss) Income($M) | 4 | 40 | -19 | 46 | -21 | 26 | -29 | 30 | -2 | -34 | -21 | 27 | |
U.S. Other Ancillary Services Operating Loss($M) | -6 | -8 | -6 | -4 | -4 | -5 | -4 | -7 | -2 | -2 | -6 | -19 | |
International Dialysis Operations Operating Income($M) | -16 | 25 | 30 | -4 | 27 | 36 | 30 | ||||||
Corporate Administrative Support Expenses($M) | -26 | -16 | -30 | -32 | -26 | -42 | -34 | -29 | -29 | -25 | -30 | -63 | |
Routine Maintenance Capital Expenditures($M) | 112 | 123 | 74 | 108 | 119 | 90 | 95 | 119 | 104 | 86 | 85 | 119 | |
Development and Relocations Capital Expenditures($M) | 47 | 47 | 28 | 38 | 47 | 32 | 48 | 52 | 35 | 39 | 36 | 40 | |
Acquisition Capital Expenditures($M) | 3 | 5 | 34 | -1 | 108 | 10 | 85 | 3 | 53 | 105 | 18 | ||
Free Cash Flow (Non-GAAP)($M)3 | 276 | 256 | 140 | 309 | 604 | -45 | |||||||
Free Cash Flow — Trailing Twelve Months (LTM)($M) | 980 | 1,308 | 1,209 | 1,024 | 996 | 947 | 1,444 | 1,162 | 1,139 | 1,038 | 645 | 1,236 | |
Operating Cash Flow — Trailing Twelve Months (LTM)($M) | 1,870 | 2,193 | 2,027 | 1,887 | 1,893 | 1,862 | 2,337 | 2,022 | 1,960 | 1,810 | 1,462 | 2,059 | |
Distributions to Noncontrolling Interests($M) | -94 | -64 | -85 | -92 | -82 | -58 | -93 | -108 | -122 | -30 | -77 | -78 | |
Consolidated Leverage Ratio (Net Debt to LTM Consolidated EBITDA)(×)4 | 3.38 | 3.37 | 3.34 | 3.26 | 3.37 | 3.34 | 3.27 | 3.03 | 3.17 | 3.10 | 3.29 | 3.15 | |
Total Debt (Supplemental Schedule)($M) | 10,832 | 10,848 | 10,694 | 10,345 | 10,310 | 10,330 | 9,799 | 9,511 | 9,624 | 9,048 | 9,179 | 8,446 | |
Net Debt (Non-GAAP)($M) | 10,337 | 10,179 | 10,050 | 9,668 | 9,604 | 9,622 | 9,361 | 8,716 | 8,553 | 8,632 | 8,384 | 8,066 | |
Effective Interest Rate on Total Debt(%) | 5.5% | 5.4% | 5.4% | 5.5% | 5.7% | 5.7% | 5.7% | 5.7% | 5.7% | 4.3% | 4.7% | 4.4% | |
Effective Interest Rate on Senior Secured Credit Facilities(%) | 6.0% | 5.8% | 5.8% | 6.0% | 6.5% | 6.6% | 6.6% | 6.9% | 7.0% | 4.6% | 4.9% | 4.4% | |
Total Share Repurchase Amount($M)4 | 111 | 348 | 403 | 331 | 465 | 446 | 550 | 367 | 406 | 376 | 240 | 286 | |
Open Market Share Repurchase Amount($M) | 74.7 | 166 | 203 | 277 | 233 | 276 | 518 | 376 | 240 | ||||
Berkshire Hathaway Share Repurchase Agreement Amount($M) | 36.5 | 183 | 200 | 50 | 232 | 170 | 32 | 0 | 0 | ||||
Total Shares Repurchased (in Thousands)2 | 594 | 2,238 | 3,005 | 2,678 | 3,274 | 3,067 | 3,660 | 2,325 | 2,734 | 2,655 | 2,119 | 2,904 | |
Open Market Shares Repurchased (in Thousands) | 411 | 1,018 | 1,346 | 2,276 | 1,638 | 1,921 | 3,457 | 2,655 | 2,119 | ||||
Berkshire Hathaway Agreement Shares Repurchased (in Thousands) | 183 | 1,220 | 1,658 | 402 | 1,636 | 1,146 | 203 | 0 | 0 | ||||
Average Price Paid per Repurchased Share($)2 | 186 | 155 | 134 | 123 | 141 | 144 | 149 | 156 | 147 | 140 | 113 | 97.82 | |
Open Market Repurchase Average Price Paid per Share($) | 180 | 161 | 150 | 141 | 142 | 149 | 140 | 113 | |||||
Berkshire Hathaway Agreement Average Price Paid per Share($) | 200 | 150 | 121 | 141 | 147 | 156 | |||||||
Redeemable Noncontrolling Interests (Put Provisions)($M) | 1,484 | 1,561 | 1,525 | 1,532 | 1,645 | 1,661 | 1,667 | 1,696 | 1,633 | 1,575 | 1,504 | 1,499 | |
Operating Lease Right-of-Use (ROU) Assets($M)2 | 2,434 | 2,430 | 2,397 | 2,397 | 2,323 | 2,339 | 2,361 | 2,394 | 2,418 | 2,458 | 2,487 | 2,501 | |
Operating Lease Liabilities — Current($M) | 438 | 440 | 432 | 426 | 432 | 429 | 421 | 410 | 405 | 405 | 401 | 394 | |
Operating Lease Liabilities — Non-Current($M) | 2,185 | 2,186 | 2,162 | 2,176 | 2,100 | 2,125 | 2,161 | 2,210 | 2,237 | 2,281 | 2,312 | 2,330 | |
Consolidated Operating Margin(%)3 | 14.0% | 16.3% | 14.1% | 15.5% | 14.8% | 15.9% | 13.6% | 17.2% | 16.4% | 15.9% | 15.8% | 12.4% | |
Consolidated Adjusted Operating Margin (Non-GAAP)(%) | 15.7% | 16.3% | 14.1% | 16.2% | 15.1% | 16.3% | 13.6% | 14.9% | 16.4% | 15.9% | 14.6% | ||
Consolidated G&A as % of Consolidated Revenues(%) | 11.4% | 11.9% | 12.4% | 13.0% | 12.1% | 12.2% | 11.6% | 12.6% | 12.1% | 11.5% | 11.8% | 12.8% | |
Consolidated Effective Income Tax Rate(%)2 | 24.9% | 21.1% | 19.4% | 20.0% | 22.2% | 25.4% | 18.9% | 15.6% | 20.8% | 19.3% | 17.7% | 20.2% | |
Effective Income Tax Rate Attributable to DaVita Inc.(%) | 28.7% | 25.6% | 25.1% | 27.7% | 31.3% | 31.9% | 24.9% | 19.9% | 26.5% | 24.2% | 21.5% | 29.0% | |
Adjusted Effective Income Tax Rate Attributable to DaVita Inc. (Non-GAAP)(%) | 26.6% | 25.6% | 25.1% | 24.9% | 27.9% | 25.5% | 24.9% | 24.5% | 26.5% | 24.3% | 24.3% | 26.7% | |
U.S. Personal Consumption Expenditures: Health Care Services (BEA, SAAR) | 3,858.70 | 3,790.30 | 3,699.90 | 3,667.00 | 3,614.90 | 3,529.80 | 3,464.70 | 3,417.80 | 3,358.20 | 3,288.20 | 3,244.40 | 3,159.40 | |
Baxter International Inc. (NYSE: BAX) — Revenue($M)1 | 2,976 | 2,960 | 2,701 | 2,974 | 2,835 | 2,810 | 2,625 | 2,753 | 2,699 | 2,694 | 2,490 | 2,729 | |
Baxter International Inc. (NYSE: BAX) — Operating Income($M) | 225 | 217 | 66 | -729 | 172 | 191 | 58 | -435 | 155 | 179 | 115 | 304 | |
Universal Health Services, Inc. (NYSE: UHS) — Revenue($M)1 | 4,733 | 4,638 | 4,495 | 4,486 | 4,495 | 4,284 | 4,100 | 4,114 | 3,963 | 3,908 | 3,844 | 3,704 | |
Universal Health Services, Inc. (NYSE: UHS) — Operating Income($M) | 454 | 517 | 503 | 517 | 522 | 500 | 455 | 472 | 384 | 436 | 389 | 331 | |
Encompass Health Corp. (NYSE: EHC) — Revenue($M) | 1,610 | 1,597 | 1,587 | 1,545 | 1,478 | 1,458 | 1,455 | 1,405 | 1,351 | 1,301 | 1,316 | 1,247 | |
Quest Diagnostics Inc. (NYSE: DGX) — Revenue($M)1 | 3,097 | 3,043 | 2,895 | 2,806 | 2,816 | 2,761 | 2,652 | 2,621 | 2,488 | 2,397 | 2,366 | 2,288 | |
Quest Diagnostics Inc. (NYSE: DGX) — Operating Income($M) | 479 | 459 | 399 | 386 | 386 | 438 | 346 | 361 | 330 | 355 | 300 | 267 | |
Labcorp Holdings Inc. (NYSE: LH) — Revenue($M)1 | 3,810 | 3,731 | 3,538 | 3,516 | 3,564 | 3,527 | 3,345 | 3,329 | 3,282 | 3,221 | 3,177 | 3,033 | |
Labcorp Holdings Inc. (NYSE: LH) — Operating Income($M) | 402 | 452 | 381 | 268 | 397 | 394 | 326 | 216 | 254 | 295 | 321 | -123 | |
HCA Healthcare, Inc. (NYSE: HCA) — Revenue($M) | 19,849 | 20,230 | 19,109 | 19,513 | 19,161 | 18,605 | 18,321 | 18,285 | 17,487 | 17,492 | 17,339 | 17,303 | |
Consolidated Operating Revenues($M)5 | 3,578 | 3,554 | 3,416 | 3,620 | 3,420 | 3,380 | 3,224 | 3,295 | 3,264 | 3,187 | 3,071 | 3,146 | |
Consolidated Operating Expenses and Charges($M) | 3,079 | 2,975 | 2,934 | 3,059 | 2,915 | 2,842 | 2,785 | 2,729 | 2,729 | 2,680 | 2,587 | 2,756 | |
Consolidated General and Administrative Expenses($M) | 409 | 424 | 422 | 472 | 414 | 413 | 374 | 415 | 394 | 368 | 363 | 402 | |
Consolidated Depreciation and Amortization($M) | 165 | 168 | 178 | 180 | 178 | 175 | 177 | 167 | 187 | 176 | 187 | 186 | |
Goodwill and Asset Impairment Charges($M) | 62.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26.1 | |
Equity Investment Income, Net($M) | 8.20 | 8.20 | 8.30 | 9.90 | 10.2 | 7.40 | 5.60 | 10.3 | 3.70 | 5.50 | 6.70 | 5.40 | |
Consolidated Operating Income($M)6 | 499 | 579 | 482 | 561 | 506 | 538 | 439 | 565 | 535 | 506 | 484 | 390 | |
Income Before Income Taxes($M) | 359 | 435 | 341 | 383 | 309 | 369 | 286 | 414 | 373 | 371 | 372 | 289 | |
Income Tax Expense($M) | 89.3 | 91.8 | 66.2 | 76.7 | 68.6 | 93.7 | 54.1 | 64.5 | 77.7 | 71.7 | 65.8 | 58.5 | |
Consolidated Net Income($M) | 269 | 343 | 275 | 331 | 240 | 275 | 232 | 349 | 296 | 300 | 306 | 231 | |
Less: Net Income Attributable to Noncontrolling Interests($M) | 46.5 | 77.8 | 77.5 | 96.8 | 89.9 | 75.9 | 69.3 | 89.9 | 81.1 | 77.1 | 66.3 | 79.9 | |
Diluted Earnings per Share($) | 3.40 | 4.02 | 2.87 | 2.04 | 2.58 | 2 | 2.50 | 2.50 | 2.65 | ||||
Weighted-Average Diluted Shares(M) | 65.5 | 66.1 | 68.9 | 73.8 | 77.4 | 81.3 | 85.8 | 89 | 90.5 | ||||
Operating Cash Flow($M)5 | 519 | 490 | 321 | 541 | 842 | 324 | 180 | 548 | 810 | 799 | -135 | 485 | |
Capital Expenditures (Cash Flow Statement)($M) | 160 | 170 | 102 | 145 | 166 | 121 | 143 | 171 | 139 | 125 | 121 | 159 | |
Stock-Based Compensation Expense($M) | 29.2 | 26 | 28.2 | 38.4 | 39 | 32.8 | 29.8 | 27.4 | 26.6 | 24.3 | 24.5 | 30.1 | |
Common Stock Repurchases (Cash Flow Statement)($M) | 73 | 182 | 196 | 275 | 240 | 284 | 510 | 365 | 408 | 362 | 251 | 272 | |
Net Cash Used in Investing Activities($M) | -420 | -194 | -139 | -163 | -263 | -67.2 | -162 | -248 | -147 | -162 | -215 | -168 | |
Net Cash Used in Financing Activities($M) | -271 | -270 | -213 | -415 | -582 | 4.40 | -383 | -565 | -7.90 | -563 | 319 | -403 | |
Consolidated Total Assets($M)5 | 17,817 | 17,710 | 17,499 | 17,480 | 17,556 | 17,493 | 17,119 | 17,285 | 17,504 | 17,026 | 17,431 | 16,894 | |
Cash and Cash Equivalents($M) | 496 | 669 | 644 | 676 | 795 | 797 | 525 | 880 | 1,159 | 503 | 431 | 465 | |
Patient Accounts Receivable, Net($M) | 2,509 | 2,467 | 2,459 | 2,415 | 2,333 | 2,441 | 2,322 | 2,147 | 2,267 | 2,303 | 2,595 | 1,987 | |
Inventories($M) | 162 | 152 | 142 | 161 | 139 | 146 | 151 | 135 | 129 | 127 | 146 | 143 | |
Goodwill($M) | 7,548 | 7,591 | 7,582 | 7,545 | 7,544 | 7,466 | 7,416 | 7,375 | 7,228 | 7,201 | 7,230 | 7,113 | |
Intangible Assets, Net($M) | 221 | 229 | 229 | 222 | 220 | 212 | 205 | 197 | 198 | 192 | 201 | 203 | |
Consolidated Total Liabilities($M)2 | 16,691 | 16,630 | 16,451 | 16,322 | 16,215 | 15,940 | 15,459 | 15,194 | 15,284 | 14,601 | 14,795 | 14,150 | |
Accounts Payable($M) | 662 | 716 | 691 | 696 | 656 | 594 | 596 | 547 | 488 | 494 | 490 | 515 | |
Long-Term Debt($M) | 10,657 | 10,664 | 10,514 | 10,164 | 10,184 | 10,079 | 9,560 | 9,176 | 9,260 | 8,452 | 9,001 | 8,268 | |
32 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- DaVita Inc.'s fiscal year ends December 31. In the project database and SEC filings, quarterly periods are labeled through Q3 2026 (ended September 30, 2026) and annual periods through FY2025 (ended December 31, 2025).
- Quarterly flow metrics from Form 10-Q / 10-K cumulative tables (Outpatient Dialysis Center Rollforward, Note 2 Disaggregated Revenue by Payor Source, Note 18 Open Market vs. Berkshire Hathaway Share Repurchases, and Consolidated Cash Flows) have Q2, Q3, and Q4 split from year-to-date totals (Q2 = 6M − Q1, Q3 = 9M − 6M, Q4 = FY − 9M) on the same accounting basis.
- For DaVita (UK) Limited (#05882395), operating subsidiary net profit is derived as Consolidated Group profit/loss minus Standalone Parent Company profit/loss from the audited UK Companies House statutory accounts (subject to intercompany management recharges and dividend eliminations).
- Internal cross-checks verified at build time: (1) U.S. Dialysis + Ancillary/International sub-segment revenues less intersegment eliminations reconcile to Consolidated Operating Revenues ($13,643M in FY2025; $3,578M in Q3 2026); (2) U.S. + International ending outpatient dialysis centers reconcile exactly to Total Global Outpatient Dialysis Centers (2,657 + 563 = 3,220 at FY2025; 2,650 + 577 = 3,227 at Q3 2026); (3) all 46 U.S. states and D.C. in the 10-K map sum to Consolidated U.S. Outpatient Dialysis Centers.
Không hiện vì thiếu các kỳ gần đây (13)
- Panama Outpatient Dialysis Centers (FY2025: 16 centers) — Entered Panama in FY2025; only 1 annual period available (requires 2 consecutive years).
- Taiwan Outpatient Dialysis Centers (FY2016–FY2019: 15, 16, 2, 1 centers) — Discontinued after FY2019 following exit from Taiwan market; lacks recent periods.
- India Outpatient Dialysis Centers (FY2016–FY2017: 21, 24 centers) — Discontinued after FY2017 following exit from India market; lacks recent periods.
- Consolidated Variable Interest Entities (VIE) Assets and Liabilities (FY2016–FY2019) — XBRL tag discontinued after FY2019.
- Goodwill by Segment (U.S. Dialysis vs. Ancillary Services, FY2016–FY2020) — Discontinued in Item 7 table after FY2020.
- Fixed-Rate Debt Percentage and Capped Debt Percentage (FY2019Q1–FY2025Q3) — Not reported in Q4 2025 or FY2026 8-K supplemental debt schedules.
- Noncontrolling Interest Contributions to Free Cash Flow (FY2022Q1–FY2026Q1) — Not reported as a separate reconciliation line in Q2–Q3 2026.
- DaVita International Limited (#11015209) Middle East Turnover (FY2020–FY2023) — Reported as £0 / not separately broken out in FY2024–FY2025 statutory accounts.
- DaVita (UK) Trading Limited (#07700242) Turnover Breakdown into Facilities Management Services vs. Management Recharges (FY2020–FY2023) — Not disaggregated in FY2024–FY2025 statutory accounts.
- U.S. Census Bureau QSS Outpatient Care Centers Quarterly Revenue (REV6214TAXABL144QNSA) — Published with a 1-quarter lag (through Q2 2026 vs. DaVita Q3 2026).
- Referring Nephrologists Count ('Nearly 5,200 nephrologists' in FY2025 10-K) — Excluded because disclosed only as a bound ('nearly').
- Home Dialysis Patient Share ('More than 15% of our patients' in Community Care Report) — Excluded because disclosed only as a bound ('more than').
- Kidney Transplant Recipients ('7,800+ DaVita patients' in Community Care Report) — Excluded because disclosed only as a lower bound ('+').
Dữ liệu cập nhật 2026-11-10.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
U.S. Dialysis Treatment Volume, Days & Organic Growth
Global Outpatient Dialysis Center Network, Patient Census & Rollforward
U.S. Dialysis Unit Economics, Modality Mix & Revenue by Payor Source
- U.S. Dialysis Average Patient Service Revenue per Treatment ($)29 kỳ
- U.S. Dialysis Patient Care Costs per Treatment ($)29 kỳ
- U.S. Dialysis General and Administrative Expenses per Treatment ($)29 kỳ
- U.S. Dialysis Depreciation and Amortization per Treatment ($)21 kỳ
- U.S. Dialysis Total Operating Revenues ($M)29 kỳ
- U.S. Dialysis Total Operating Expenses ($M)29 kỳ
- U.S. Dialysis Segment Operating Income ($M)29 kỳ
- U.S. Dialysis Patient Accounts Receivable ($M)29 kỳ
Integrated Kidney Care (IKC), Ancillary & International Sub-Segments
Capital Allocation, CapEx Breakdown, Leverage, Share Repurchases & Leases
- Routine Maintenance Capital Expenditures ($M)29 kỳ
- Development and Relocations Capital Expenditures ($M)29 kỳ
- Acquisition Capital Expenditures ($M)27 kỳ
- Proceeds from Sale of Self-Developed Properties ($M)6 kỳ
- Free Cash Flow (Non-GAAP) ($M)23 kỳ
- Consolidated Leverage Ratio (Net Debt to LTM Consolidated EBITDA) (×)29 kỳ
- Total Share Repurchase Amount ($M)24 kỳ
- Redeemable Noncontrolling Interests (Put Provisions) ($M)43 kỳ
- Operating Lease Right-of-Use (ROU) Assets ($M)32 kỳ
- Consolidated Operating Margin (%)29 kỳ
International & UK Subsidiaries (Companies House Statutory Filings)
Workforce, 401(k) Benefit Plan & Environmental Sustainability
- Global Teammate Headcount10 kỳ
- CEO to Median Teammate Pay Ratio (×)5 kỳ
- DaVita Retirement Savings 401(k) Plan — Net Assets Available for Benefits ($M)6 kỳ
- Total Energy Consumed6 kỳ
- Total Water Withdrawals (in Megaliters)6 kỳ
- Scope 1 Direct Greenhouse Gas Emissions6 kỳ
- Scope 2 Location-Based Greenhouse Gas Emissions6 kỳ
- Scope 3 Value Chain Greenhouse Gas Emissions6 kỳ
- Total Waste Generated6 kỳ
Industry Macro Indicators, Federal VA Contracts & Peer Benchmarks
- U.S. Federal Government Contract Obligations to DaVita Inc. (USAspending) ($M)117 kỳ
- U.S. Outpatient Care Centers Employment (BLS CES6562140001, SA)129 kỳ
- U.S. Personal Consumption Expenditures: Health Care Services (BEA, SAAR)43 kỳ
- U.S. CPI-U: Medical Care Services (BLS CUSR0000SAM2, SA)128 kỳ
- Fresenius Medical Care AG (NYSE: FMS) — Global Revenue (IFRS 20-F) (€M)10 kỳ
- Baxter International Inc. (NYSE: BAX) — Revenue ($M)43 kỳ
- Universal Health Services, Inc. (NYSE: UHS) — Revenue ($M)43 kỳ
- Encompass Health Corp. (NYSE: EHC) — Revenue ($M)43 kỳ
- Quest Diagnostics Inc. (NYSE: DGX) — Revenue ($M)43 kỳ
- Labcorp Holdings Inc. (NYSE: LH) — Revenue ($M)43 kỳ
- HCA Healthcare, Inc. (NYSE: HCA) — Revenue ($M)23 kỳ
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của DaVita
- DaVita Inc. Form 8-K (0000927066-26-000132) ↗
- DaVita Inc. Form 8-K (0000927066-26-000004) ↗
- DaVita Inc. Form 10-Q (0000927066-26-000134) ↗
- DaVita Community Care & SASB ESG Report (esg:2025-davita-community-care-report.pdf) ↗
- DaVita Inc. Form 10-K (0000927066-26-000012) ↗
- Baxter International Inc. SEC XBRL Filings ↗
- Universal Health Services, Inc. SEC XBRL Filings ↗
- Encompass Health Corp. SEC XBRL Filings ↗
- Quest Diagnostics Inc. SEC XBRL Filings ↗
- Labcorp Holdings Inc. SEC XBRL Filings ↗
- HCA Healthcare, Inc. SEC XBRL Filings ↗
- UK Companies House Statutory Accounts — DaVita International Limited (#11015209, uk_11015209_AA_2025) ↗
See a number that looks wrong?